Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19

Michalis Liontos; Maria Kaparelou; Emmanouil Karofylakis; Dimitra Kavatha; Andreas Mentis; Flora Zagouri; Evangelos Terpos; Meletios-Athanasios Dimopoulos

doi:10.1016/j.gore.2020.100615

Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19

Gynecol Oncol Rep. 2020 Jul 30:33:100615. doi: 10.1016/j.gore.2020.100615. eCollection 2020 Aug.

Authors

Michalis Liontos¹, Maria Kaparelou¹, Emmanouil Karofylakis², Dimitra Kavatha², Andreas Mentis³, Flora Zagouri¹, Evangelos Terpos¹, Meletios-Athanasios Dimopoulos¹

Affiliations

¹ Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.
² 4th Department of Internal Medicine, University Hospital « Attikon », 1 Rimini Avenue, 12462 Haidari, Athens, Greece.
³ Laboratory of Medical Microbiology, Hellenic Pasteur Institute, Athens, Greece.

Abstract

•Chemotherapy resumption after convalescence from COVID-19 is safe and feasible.•No guidelines exist for resumption of chemotherapy in patients with COVID-19.•Cancer patients on chemotherapy may develop SARS-CoV-2 antibodies less frequently.

Publication types

Case Reports